Zepzelca (Lurbinectedin): New Hope For Small Cell Lung Cancer Treatment
Jazz Pharmaceuticals recently announced that its anticancer drug Zepzelca (Lurbinectedin Injection) in combination with Atezolizumab (Tecentriq) achieved significant overall survival (OS) and progression-free survival (PFS) improvements in the first-line maintenance treatment of extensive-stage small cell lung cancer (ES-SCLC). PFS) improvements.
This breakthrough offers new hope for patients with this aggressive form of lung cancer.
Zepzelca Clinical Trial Results
In the Phase III clinical trial called IMforte, the combination therapy of Zepzelca drug with Atezolizumab significantly prolonged patient survival and progression-free survival compared to Atezolizumab alone.
Trial data showed that the combination therapy demonstrated statistically significant improvements in both primary endpoints (OS and PFS).
Jazz Pharmaceuticals plans to submit a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) in the first half of 2025 to support the combination therapy as a first-line maintenance treatment for ES-SCLC in this indication.
Mechanism Of Action Of Zepzelca Drug
Zepzelca drug is an alkylating agent that affects the activity of DNA-binding proteins by binding to guanine residues in DNA, interfering with the cell cycle and ultimately leading to cancer cell death.
Lurbinectedin FDA approval in 2020 for the treatment of patients with metastatic small cell lung cancer whose disease has progressed following platinum-based chemotherapy.
Safety Data
Preliminary safety data showed that the safety profile of the combination therapy was consistent with the known safety profile of Lurbinectedin Injection and Atezolizumab, and no new safety signals were identified.
Common adverse reactions include fatigue, leukopenia, and abnormal liver function.
Future Outlook
Jazz Pharmaceuticals plans to further advance Zepzelca indication expansion in 2025, including the filing of a marketing authorization application (MAA) in Europe.
Additionally, the company is conducting the LAGOON Phase III clinical trial to validate Lurbinectedin Injection efficacy in relapsed small-cell lung cancer and support its full approval in the U.S.
However, DengYue’s efforts to increase the affordability of the medicine are critical to ensuring that more patients benefit from it.
We welcome you to reach out to us to get zepzelca cost. DengYueMedicine is here to provide detailed medicine information, pricing, and support to ensure a smooth and reliable buying experience.
Feel free to contact us anytime to discuss your needs or ask any questions about the medicine.
Information from DengYueMed, China Drug Import and Export Wholesaler offers this information as a guide, not a substitute for professional medical advice. Consult your doctor before any treatment.
